ZYME Zymeworks Inc.

$26.24▼ -0.74% Healthcare Other
After hours $26.07▼ -0.65% Sep 11, 7:30 PM ET
Volume 574.6K Avg Volume (10D) 586.5K
Key Metrics & Fundamentals
Market Cap
$1.88B
P/E Ratio
–
Div Yield
–%
52W Range
15.49 - 31.34
% vs 50 MA
2.27%
% vs 200 MA
4.75%
RSI-14
45.6
MACD Histogram
-0.4300
Beta (1Y vs SPY)
0.67
Free Cash Flow
-$31.95M
Gross Rev
$4.59M
Gross Profit
$4.59M
EBITDA
-$36.74M
COGS
–
Operating Exp
$46.74M
Operating Income
-$42.15M
EBIT
-$42.15M
Pretax Income
-$45.29M
Net Income
-$45.02M
EPS (Diluted)
-0.62
Price & Volume History
Loading chart…
Recent News
JAZZ Rises on Updated OS Results From Gastric Cancer Study
Zacks · Sep 1, 2026 4:02 PM
Zymeworks (ZYME), What Is Behind The Renewed Attention?
Simply Wall St. · Aug 28, 2026 7:05 PM
Is Zymeworks (ZYME) Stock Fully Priced After Its 301% Run?
Simply Wall St. · Aug 28, 2026 9:07 AM
Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer Regimens
Benzinga · Aug 27, 2026 8:31 PM
SJM, ZYME Stocks Hit 52-Week High – What’s Driving The Surge Today?
Stocktwits · Aug 26, 2026 5:59 PM
JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer
Zacks · Aug 26, 2026 4:29 PM
Jazz Pharmaceuticals Launches Ziihera After FDA Nod in HER2-Positive GEA
MarketBeat · Aug 26, 2026 12:02 AM
New Jazz cancer drug approval could drive blockbuster sales
BioPharma Dive · Aug 25, 2026 5:21 PM
JAZZ, ONC, ZYME Stocks In Focus After FDA Approves Gastroesophageal Cancer Therapy
Stocktwits · Aug 25, 2026 4:26 PM
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
GlobeNewswire · Aug 25, 2026 2:23 PM
Financial Overview - Income Statement Quarterly

See ZYME's money flow as a full page

Social Sentiment
Avg +0.70 · 2 posts
DDTradePriceTargetZYME stock?
r/wallstreetbets · Jun 24, 2026
The author believes the stock is undervalued and anticipates a significant increase, expressing optimism about its potential.
positive +0.80
AI Memory Hardware, Pharma & Strategic Industries – Watchlist 2026
r/stocks · Nov 23, 2025
ZYME is highlighted as a ‘Strong Phase III’ biotech with blockbuster potential, indicating a bullish assessment.
positive +0.60
AI Analysis

Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.

Not financial advice. All data, scores, charts, and analysis on this site are provided for informational and educational purposes only and do not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. See our Legal Notice for full details.
An unhandled error has occurred. Reload 🗙